Australia’s Therapeutic Goods Administration has approved BioMimetic Therapeutics’ Augment bone graft for marketing and listing on the Australian Register of Therapeutic Goods.

Augment is a completely synthetic two-component grafting system for bone regeneration.

It is composed of a purified bone and tissue growth factor, recombinant human platelet-derived growth factor and beta-tricalcium phosphate, a synthetic calcium-phosphate matrix.

Recombinant human platelet-derived growth factor provides the biological stimulus for tissue repair by stimulating the recruitment and proliferation of new bone forming and wound healing cells and blood vessels, while the beta-tricalcium phosphate provides the scaffold for new bone growth to occur.

The approval is backed by the clinical data from a North American pivotal trial and Canadian registration trial.

BioMimetic Therapeutics president and CEO Samuel Lynch said that the company is finalising pricing and reimbursement, and expects to fully launch the product in the first quarter of 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also plans to seek European approval during the first half of 2012.